Rare Disease - Medika Life

Although rare by definition, the collective impact of rare diseases is anything but insignificant. In the Asia-Pacific (APAC) region – home to over half of...

Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients

Gil Bashe, Medika Life Editor - July 30, 2025

Craig Martin is a strategic chameleon in health innovation. He is equally at home in boardrooms, nonprofit leadership, consulting and advisory roles, all with...

Reevaluating Ehlers-Danlos Syndrome: How Vascular EDS Patients Are Left Behind

Gil Bashe, Medika Life Editor - October 21, 2024

EDS Subtyping May Not Be a Harmless Convention, But a Recipe for Patient Danger

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

Treating Rare Diseases: The Challenge of Access

Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients

Biotech Without Borders: Reclaiming the Wonder of Science in a Distracted Age

Real-World Evidence Unlocks Consumer Voice to Improve Care

LATEST

TRENDING

Reevaluating Ehlers-Danlos Syndrome: How Vascular EDS Patients Are Left Behind

The Disorder That Makes Monster Faces Out of Everyone You See

HPV Urban Legends – From Contagion to Symptoms to Risks to Prevention – There Are More Rare Concerns that Deserve Our Attention

Looking for Zebras: Listening to Patients, Healing the Health System

Real-World Evidence Unlocks Consumer Voice to Improve Care

India’s Pivotal Regulatory Shift: A Possible Game-Changer in Expediting Medicines to Millions in Dire Need

Biotech Without Borders: Reclaiming the Wonder of Science in a Distracted Age

The New Covid Vaccine Is Out. Why You Might Not Want To Rush To Get It

Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients

StuffThatWorks and The Marfan Foundation to Engage in Pilot Program

EDITORS CHOICE

Real-World Evidence Unlocks Consumer Voice to Improve Care

Treating Rare Diseases: The Challenge of Access

Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients

Reevaluating Ehlers-Danlos Syndrome: How Vascular EDS Patients Are Left Behind

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories